Palvella Therapeutics, Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/fb038b69-3d82-41ff-9918-8bfa9f89c717/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-38.6M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-133372 |
| FY 2024 | $-14.1M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-047212 |
| FY 2023 | $-11.9M | 2023-01-01 – 2023-12-31 | evidence 0000950170-25-047212 |
| FY 2022 | $-43.5M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-008834 |
| FY 2021 | $-51.8M | 2021-01-01 – 2021-12-31 | evidence 0001583648-22-000016 |
| FY 2020 | $-33.9M | 2020-01-01 – 2020-12-31 | evidence 0001583648-21-000005 |
| FY 2019 | $-27.2M | 2019-01-01 – 2019-12-31 | evidence 0001583648-20-000015 |
| FY 2018 | $-30.8M | 2018-01-01 – 2018-12-31 | evidence 0001583648-19-000011 |
| FY 2017 | $-14.6M | 2017-01-01 – 2017-12-31 | evidence 0001583648-18-000017 |
| FY 2016 | $-22.8M | 2016-01-01 – 2016-12-31 | evidence 0001583648-18-000017 |
| FY 2015 | $-13.7M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-514870 |
| FY 2014 | $-7.2M | 2014-01-01 – 2014-12-31 | evidence 0001193125-16-514870 |
| FY 2013 | $-9.5k | 2013-05-24 – 2014-03-31 | evidence 0001583648-14-000007 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Palvella Therapeutics, Inc. — all facts · Revenue · Net Income